Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Inclusion Criteria: * Must be able to understand and voluntarily sign an informed consent form (ICF). * Must be ≥ 18 years of age at the time of signing the ICF * Must be able to adhere to the study visit schedule and other protocol requirements. * Relapsed and/or refractory MM with: * Documented evidence of progressive disease (PD) after achieving at least stable disease (SD) for ≥ 1 cycle during a previous MM treatment (i.e., relapsed MM). OR Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM). * Previously undergone treatment with at least one immunomodulatory drug (lenalidomide or pomalidomide), one proteasome inhibitor (bortezomib, ixazomib, carfilzomib) and one anti-CD38 drug (daratumumab or isatuximab). These drugs could have been used in separate regimens or in combination. * No effective standard of care options available * Patients with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: * transplant was \> 12 weeks prior to study enrolment * no active infection * Patients with measurable disease defined as at least one of the following (these baseline laboratory studies for determining eligibility must be obtained within 28 days prior to start of study drug): * Serum M-protein ≥ 0.5 g/dl (≥ 5 g/l) * Urine M-protein ≥ 200 mg/24 h * Serum free light chains (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) and an abnorma…